profit from every $100 of sales.
$0$100
Elutia
$0.92-1.38% today
+11.7% in 1 year
1-year low $0.501-year high $1.22
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $0.76 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Elutia sold, what it kept, and what it did with the cash.
Sales went from $23.8 million in 2022 to $12.3 million in 2025, with $53.4 million of profit last year.
SalesProfit
Elutia vs. similar companies
Elutia grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Elutia | 0.8× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Elutia's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 24 | 25 | 14 | 12 | |
| 12 | 11 | 7 | 7 | |
| -30 | -21 | -19 | -18 | |
| -27 | -32 | -41 | -16 | |
| -33 | -38 | -54 | 53 | |
| -2.38 | -2.07 | -1.86 | 0.87 | |
| 48.8% | 44.7% | 46.4% | 53.7% | |
| -125.7% | -83.0% | -133.7% | -149.8% | |
| -137.9% | -152.2% | -372.9% | 434.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 69 | 43 | 36 | 62 |
| Cash | 17 | 19 | 13 | 36 |
| Total debt | 24 | 24 | 24 | 4 |
| Total liabilities | 74 | 82 | 82 | 35 |
| -5 | -39 | -46 | 28 | |
| 14 | 18 | 29 | 46 | |
| -126.0% | – | – | -46.0% | |
| 653.6% | 97.6% | 116.6% | 192.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -22 | -23 | -45 | |
| 1 | 0 | 1 | 2 | |
| -22 | -22 | -23 | -47 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 2 | 8 | 5 |
Valuation
- 0.8×
- –
- –
- 2.3×
- 3.3×
- –
- –
- -114.6%
- 131.0%
- 0.0%
Profitability
- 53.7%
- -149.8%
- 434.2%
- -113.8%
- -79.6%
- 86.1%
- -560.6%
- 90.3%
- -80.9%
- 35.9%
Growth
- −19.8%
- –
- −100.3%
- –
- +41.1%
Financial health
- -2.1×
- 0.27
- 11.0%
- 8.6×
- 2.05
- 1.94
- 0.29
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 958
Bottom 2%of 888
Top 1%of 600
Bottom 4%of 889
What analysts expect
- Average price target
- $8.88
- Range
- $5.00 – $10.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.17 | -0.15 | −13.3% |
| Mar 11, 2026 | -0.14 | -0.14 | +0.0% |
| Nov 6, 2025 | -0.01 | -0.16 | +93.5% |
| Aug 14, 2025 | -0.26 | -0.17 | −52.9% |
| May 8, 2025 | -0.21 | -0.20 | −5.0% |
| Mar 6, 2025 | -0.26 | -0.25 | −4.0% |
| Nov 14, 2024 | -0.33 | -0.44 | +25.0% |
| Aug 7, 2024 | -1.14 | -0.33 | −245.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
67Pass
Benjamin Graham
62Pass
Philip Fisher
56No pass
Peter Lynch
40No pass
Joel Greenblatt
4No pass
Charlie Munger
58No pass
Terry Smith
50No pass
Questions about Elutia
Is Elutia a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Elutia AI analysis
What does Elutia do?
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It is in Biotechnology.
Does Elutia pay a dividend?
No. Elutia does not pay a dividend at the moment.
Is Elutia stock halal?
No. Elutia does not pass our halal screen: its cash and confirmed interest-bearing investments are 89% of its market value, at or above the 33% limit. How we check
How has Elutia stock done over the past year?
Up 11.7% over the past twelve months, to $0.92. It traded between $0.50 and $1.22 and is 24.6% below its high.
Who are Elutia's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Elutia's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.